PROF

Profound Medical

Fundamental data last updated:March 2, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical Devices

Exchange

Nasdaq

County of HQ

Canada

Next Earnings Date

4

Business Summary

Profound Medical develops and commercializes medical device technologies focused on minimally invasive therapeutic treatments. The company’s systems are designed to use advanced energy-based technologies to treat targeted tissue while minimizing damage to surrounding areas.

 


Analyze PROF on TradingView

VALUATION

P/E

-

Market Cap ($M USD)

$277

Forward P/E

-

PEG

-

PRICE TO SALES

15.5

PRICE TO BOOK

8.6

EV / EBITDA

5-Year Average P/E

Free Cash Flow Yield

DCF Value

Graham Number

Price to FCF

EV to FCF

Earnings Yield

FCF Yield

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$1.32

Next Year EPS Growth Estimate

-$1.03

Next Year Revenue Growth Estimate

108.00%

Return on Equity (ROE)

-122.40%

FREE CASH FLOW

Operating Margin

-295.40%

Debt-to-Equity

0.2

Piotroski F-Score

Altman Z-Score

Return on Invested Capital (ROIC)

Current Ratio

Quick Ratio

Net Debt to EBITDA

Interest Coverage

Gross Profit margin

FCF PER SHARE

REVENUE PER SHARE

Analyze PROF on TradingView

Gainseekers Quantitative Analysis

Summary

Profound Medical is a Nasdaq-listed medical devices company with a market capitalization of $277 million. The company is currently unprofitable, reporting EPS of -$1.32 and a return on equity of -122.40%, alongside a deeply negative operating margin of -295.40%. However, analysts expect significant top-line expansion with 108.00% projected sales growth next year and an improvement in EPS to -$1.03.

AI Exposure / Tech Reliance

As a medical device company, its growth likely depends on advanced technology integration and continued innovation in its treatment platforms. Its valuation at 15.5 times sales suggests investors are pricing in strong future technology-driven adoption.

The Bull Case

The company is projected to grow sales by 108.00% next year, indicating potential commercial acceleration. Analyst sentiment is favorable with a consensus rating of 1.6 and a mean target price of $12.56, suggesting upside from current levels.

The Bear Case

Profitability remains a major concern, with a -295.40% operating margin and -122.40% return on equity highlighting significant losses. The stock also trades at elevated valuation multiples, including a price-to-sales ratio of 15.5 and price-to-book of 8.6, which could pressure shares if growth expectations are not met.

Market Sentiment & Smart Money

Short Interest %

4.40%

Analyst Consensus

1.6

Average Analyst Price Target

$12.56

Institutional Ownership %

45.40%

1-Year Beta

Insider Buying % (6 Mo)

Distance to 52-Week High

Distance to 52-Week Low

EARNINGS SURPRISE %

50-DAY SMA

200-DAY SMA

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.